41 The gain in life expectancy was 4 years when HSCT was performed in MDS patients with intermediate risk according to WPSS, in contrast to patients considered intermediate-1 risk according to IPSS.64 The difference between the 2 risk classifications is mainly based on the consideration of ...
While symptomatic management and supportive care are the mainstay of therapy for patients with LR-MDS, patients with higher-risk MDS (HR-MDS; i.e., IPSS-R > 3.5) have a substantial risk of progression to AML and a reduced life-expectancy warranting a more aggressive, disease-modifying appro...